Zobrazeno 1 - 10
of 14
pro vyhledávání: '"MJ Company Albir"'
Autor:
R Iglesias Gómez, F Luna, J Moya Sola, M Tordera Baviera, MJ Company Albir, T Palanques Pastor, I Beltran Garcia, JL Poveda Andres
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance Most decisions made in clinical practice are based on the results of published clinical trials (CT). A widely used tool for the evaluation of the methodological quality of publications of randomised clinical trials (RCTs) ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd0061279f51b1a4040d229e2a1a9f45
https://doi.org/10.1136/ejhpharm-2020-eahpconf.33
https://doi.org/10.1136/ejhpharm-2020-eahpconf.33
Autor:
Ana Gimeno-Navarro, I Izquierdo-Macián, José Luis Poveda-Andrés, R Escrig-Fernández, MJ Company-Albir, AA García Robles, O Ballesta-López
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance The control of pain and sedation is a challenge in the neonatal intensive care unit (NICU). Traditionally, opioids and benzodiazepines have been the most commonly used, but they have side effects. Dexmedetomidine, an alpha a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8046d2198805ef5b45ca854981813591
https://doi.org/10.1136/ejhpharm-2020-eahpconf.237
https://doi.org/10.1136/ejhpharm-2020-eahpconf.237
Autor:
A Ferrada Gascó, JE Megías Vericat, MJ Company Albir, AA García Robles, C Favieres Puigcerver, O Ballesta López, MJ Fernández Megía, FC Pérez Miralles, JL Poveda Andrés, B Casanova Estruch
Publikováno v:
Clinical pharmacy.
Background Progressive multifocal leukoencephalopathy(PML) is caused by JC virus (JCV) and has severe consequences for the central nervous system. PML is an opportunistic infection, affecting HIV positive patients. There is no curative treatment, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8d26969327d36c0e2b3c940389d088a
https://doi.org/10.1136/ejhpharm-2017-000640.69
https://doi.org/10.1136/ejhpharm-2017-000640.69
Autor:
AA García Robles, MJ Company Albir, JE Megías Vericat, A Ferrada Gascó, MJ Fernández Megía, FC Pérez Miralles, C Alcalá Vicente, I Boscá Blasco, JL Poveda Andrés, B Casanova Estruch
Publikováno v:
Clinical pharmacy.
Background Inaccessibility of inflammation compartmentalised to the CNS may underlie the lack of effectiveness of immunomodulatory treatments in progressive multiple sclerosis (PMS), turning its treatment into a challenge for researches. Intrathecal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac8d7b62f2279fecdd0251f7fb830158
https://doi.org/10.1136/ejhpharm-2017-000640.219
https://doi.org/10.1136/ejhpharm-2017-000640.219
Autor:
M Martin Cerezuela, A Vazquez Polo, E López Briz, R Luna Reina, C Favieres Puigcerver, MJ Company Albir, H Ribes Artero, A Solana Altabella, A Ferrada Gasco, JL Poveda Andrés
Publikováno v:
Clinical pharmacy.
Background The preparation of total parenteral nutrition (TPN) is subject to a great deal of variability in clinical practice due to the complexity of TPN and the variety of professionals involved. Nutritional support is an important care activity in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4205adae41a9129d0c992b89f7d86802
https://doi.org/10.1136/ejhpharm-2017-000640.138
https://doi.org/10.1136/ejhpharm-2017-000640.138
Autor:
C Favieres Puigcerver, E López Briz, A Melero Zaera, P Pérez Huertas, MJ Company Albir, AA García Robles, M Martín Cerezuela, R Luna Reina, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 23:A132.1-A132
Background Cytomegalovirus disease is an important cause of morbidity and mortality in haematopoietic stem cell transplantation (HSCT) recipients. Foscarnet, an intravenous drug active against cytomegalovirus, represents an increasingly widespread al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cb2b57d93a2b5422c3858b31f437310
https://doi.org/10.1136/ejhpharm-2016-000875.299
https://doi.org/10.1136/ejhpharm-2016-000875.299
Autor:
M Martín Cerezuela, A Solé Jover, MR Marqués Miñana, A Pastor Coll, J Escrivà Peiró, P Pérez Huertas, MJ Company Albir, E Ansotegui Barrera, JP Reig Mezquida, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 23:A192.1-A192
Background Therapeutic monitoring of everolimus is necessary to determine an optimal dosage regimen in lung transplantation patients to prevent graft rejection due to the narrow therapeutic window. The area under the concentration-time curve (AUC –
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c1b33a4a619e73ab1e044fb5041c372
https://doi.org/10.1136/ejhpharm-2016-000875.434
https://doi.org/10.1136/ejhpharm-2016-000875.434
Autor:
A García Robles, PG Kostadinova, C Borrell García, A Albert Marí, JE Megías Vericat, MJ Company Albir, R Sanz Martinez, P Pérez Huertas, E López Briz, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 23:A242.2-A243
Background Paclitaxel is commonly associated with infusion reactions (IR) with no clear influence of different paclitaxel formulations. Purpose To analyse the number and severity of IR related to administration of different generic formulations of pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e48d4a89b4505e88b1993ffdd198e34
https://doi.org/10.1136/ejhpharm-2016-000875.550
https://doi.org/10.1136/ejhpharm-2016-000875.550
Autor:
MJ Company Albir, AA García Robles, R Luna Reina, M Martin Cerezuela, C Favieres Puig Cerver, P Pérez Huertas, C Borrell García, P Jose Luis
Publikováno v:
European Journal of Hospital Pharmacy. 22:A61.2-A61
Background The increasing prevalence, morbidity and mortality rates of Clostridium difficile infection (CDI) turn its treatment into a challenge for researchers. Fidaxomicin is a new treatment option which has been shown to be effective for treating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::603a3182261b4a8db85486c05e8b9e20
https://doi.org/10.1136/ejhpharm-2015-000639.146
https://doi.org/10.1136/ejhpharm-2015-000639.146
Autor:
J Ruiz Ramos, MJ Company Albir, C Favieres Puigcerver, P Marrero Álvarez, JE Megias Vericat, S Valero García, E López Briz, JL Poveda Andrés
Publikováno v:
European Journal of Hospital Pharmacy. 21:A52.2-A52
Background Sinusoidal obstruction syndrome (SOS) is an important non-haematological toxicity in patients who have received chemotherapy for haematopoietic stem cell transplantation (HSCT). In March 2013, European Medicines Agency refused marketing au
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12566c8ed6d2232baf92d2fd6230a103
https://doi.org/10.1136/ejhpharm-2013-000436.127
https://doi.org/10.1136/ejhpharm-2013-000436.127